Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediPharm LabsSTU:MLZ -1.09% EV-to-OCF is -24.84 as of Aug. 28, 2026. The stock has 4 warning signs investors should review. Among 1,006 Drug Manufacturers companies, MediPharm Labs ranks better than 89.26% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, MediPharm Labs's Enterprise Value is €15.30 Mil.
MediPharm Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.62 Mil. Therefore, MediPharm Labs's EV-to-OCF for today is -24.84.
The historical rank and industry rank for MediPharm Labs's EV-to-OCF or its related term are showing as below:
STU:MLZ'
s EV-to-OCF Range Over the Past 10 Years
Min: -104.78 Med: -2.45 Max: 185.81
Current: -25.22
During the past 9 years, the highest EV-to-OCF of MediPharm Labs was 185.81. The lowest was -104.78. And the median was -2.45.
STU:MLZ's EV-to-OCF is ranked better than 89.26% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.505
vs STU:MLZ: -25.22
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MediPharm Labs's PE Ratio (TTM) for today is calculated as:
MediPharm Labs's share price for today is €0.0455.
MediPharm Labs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.006.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MediPharm Labs EV-to-OCF Related Terms
MediPharm Labs EV-to-OCF Historical Data
* Premium members only.
The historical data trend for MediPharm Labs's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's EV-to-OCF falls into.
MediPharm Labs's current Enterprise Value is €15.30 Mil.
MediPharm Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediPharm Labs (STU:MLZ) has a EV-to-OCF of -24.84 as of Aug. 28, 2026. According to the industry distribution chart, MediPharm Labs ranks #108 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 10.7%.
Is MediPharm Labs' EV-to-OCF too high?
MediPharm Labs' current EV-to-OCF is -24.84. Based on the distribution chart, MediPharm Labs ranks #108 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does MediPharm Labs' EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #108 out of 1006 companies for EV-to-OCF. This places MediPharm Labs in the top 11% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 10.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.51, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediPharm Labs's current EV-to-OCF is -24.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (STU:MLZ) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.05 — trading 13.8% above its estimated fair value. The current EV-to-OCF is -24.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For MediPharm Labs (STU:MLZ), the current EV-to-OCF is -24.84 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MLZ has been successfully added to your 
